高危前列腺癌新辅助雄激素阻断后前列腺切除术结局
汇总三项新辅助雄激素剥夺治疗(ADT)试验中72例高危前列腺癌患者,探讨RP后结局。中位随访3.4年,3年无生化复发率为70%(95%CI 57%,90%);15例残留肿瘤≤0.5cm或病理T降期者无复发。结论提示新辅助治疗可能对复发率有积极影响,需更大样本更长随访验证。
要点
- 新辅助ADT后RP,3年无生化复发率为70%(95%CI 57%,90%)。
- 15例残留肿瘤≤0.5cm或病理T降期患者中无复发。
- 需更大样本和更长随访评估新辅助激素治疗对病理及长期结局的影响。
核心结论
- 在新辅助治疗后的RP患者中,残留肿瘤≤0.5cm或病理T降期者无复发,提示新辅助治疗可能对复发率有积极影响。
- 需更大样本和更长随访评估新辅助激素治疗对病理和长期结局的影响。
研究设计与样本
- 对三项新辅助ADT试验中具有随访数据的患者进行汇总分析,共纳入72例接受RP前强化ADT的患者,来自三个机构。
- 主要终点为生化复发(BCR)时间,BCR定义为PSA≥0.2 ng/mL或因PSA升高<0.2 ng/mL而接受放疗或ADT。
主要发现
- 72例中多数Gleason评分≥8(n=46,63.9%)。
- 新辅助治疗后,55.7%(39/70)为pT3期,40%(28例)有精囊侵犯,12.9%(9例)切缘阳性,11.4%(8例)淋巴结受累。
- 11例(15.7%)肿瘤≤0.5cm,包括4例(5.7%)病理完全缓解和7例(10.0%)残留肿瘤0.1-0.5cm。
- 与治疗前临床分期相比,10例(14.3%)在RP时出现病理T降期。
- 中位随访3.4年,3年无BCR率为70%(95%CI 57%,90%);15例残留肿瘤≤0.5cm或病理T降期患者中无复发。
临床怎么用
- 在高危前列腺癌患者中,RP前新辅助ADT可能影响复发率,但需更大样本和更长随访验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS: In this analysis, we report on the post-RP outcomes of a subset of patients enrolled on these studies. We conducted a pooled analysis of patients with available follow-up data treated on three neoadjuvant trials at three institutions. All patients received intense ADT prior to RP. The primary endpoint was time to biochemical recurrence (BCR). BCR was defined as a PSA ≥ 0.2 ng/mL or treatment with radiation or androgen-deprivation therapy for a rising PSA < 0.2 ng/mL. RESULTS: Overall, 72 patients were included of whom the majority had a Gleason score ≥ 8 (n = 46, 63.9%). Following neoadjuvant therapy, 55.7% of patients (n = 39/70) had pT3 disease, 40% (n = 28) had seminal vesicle invasion, 12.9% (n = 9) had positive margins, and 11.4% (n = 8) had lymph node involvement. Overall, 11 (15.7%) had tumor measuring ≤ 0.5 cm, which included four patients (5.7%) with a pathologic complete response and seven (10.0%) with residual tumor measuring 0.1-0.5 cm. Compared to pretreatment clinical staging, 10 patients (14.3%) had pathologic T downstaging at RP. The median follow-up was 3.4 years. Overall, the 3-year BCR-free rate was 70% (95% CI 57%, 90%). Of the 15 patients with either residual tumor ≤ 0.5 cm or pathologic T downstaging, no patient experienced a recurrence. CONCLUSION: In this exploratory pooled clinical trials analysis, we highlight that neoadjuvant therapy prior to RP in unfavorable intermediate and high-risk patients may potentially have a positive impact on recurrence rates. Larger studies with longer follow-up periods are warranted to evaluate the impact of neoadjuvant hormone therapy on pathologic and long-term outcomes.
引用
- McKay RR, Montgomery B, Xie W, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2017. PMID: 29263420. doi:10.1038/s41391-017-0009-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。